If you are still with us – thank you for making it this far!
Our Life Sciences A to Z began in October 2019 and we have enjoyed covering 48 different legal topics relevant to the sector since then.
If you have a question on any of the areas we have covered throughout the A to Z, please do get in contact – our multi-disciplinary life sciences team would be delighted to assist you.
Many articles in the series relate to areas that have become hot legal topics for the life sciences industry. The recent landmark High Court decision in Cardiorentis AG v IQVIA on the conduct of clinical trials by a contract research organisation remind us of the importance of effectively negotiating a clinical trial agreement at the outset of a project.
Another key area for life sciences businesses to prioritise now is transparency, particularly given the increased industry and public demand for clearer and more objective reporting on the R&D, distribution and advertising practices involved in bringing pharmaceutical products to the market.
Over the past two years, many of us have seen a significant increase in the accessibility and uptake of telemedicine services, which are likely to continue to grow even once we are past the pandemic.
More broadly, as we have seen throughout the pandemic, collaboration between parties is often the key to finding solutions to complex problems. Our articles on joint ventures and licensing provide a useful starting point when considering what the written agreements underpinning these collaborations should include.
As always – all of our A to Z articles to date can be found here.